Transparency and Regulation: QR Group Explains the Resumption of Data Publication

Anvisa has resumed the publication of medical device price monitoring data on its Business Intelligence (BI) dashboards. This activity, previously suspended due to the Agency’s internal restructuring, once again offers crucial information for the health sector. With this resumption, companies in the segment have access to up-to-date data, allowing a better understanding of market trends and assisting in strategic planning.

Impact of the Resumption on Medical Device Regulation

The reallocation of this activity to the Executive Secretariat of the Drug Market Regulation Chamber (SCMED) led to the temporary suspension of the release of data. This process was necessary to review information and improve the methodology, ensuring greater accuracy and efficiency in the presentation of data to the public. Now, with the completion of this stage, the panels are once again an essential tool for regulatory transparency and sectoral analysis.

How QR Group Helps Manufacturers Meet Requirements

QR Group, a specialist in medical device regulation, closely follows all regulatory changes imposed by Anvisa. With an experienced team and a strategic eye for the market, we offer complete support for companies that need to ensure compliance and optimize their insertion in the Brazilian market.

Main benefits of relying on QR Group:

• Technical guidance on current regulations;
• Support for petitioning with Anvisa;
• Monitoring of requirements to ensure speed in processes;
• Strategic advice for price adequacy and registrations.

Anvisa’s monitoring of medical device prices is an important step towards strengthening transparency and regulatory certainty. With this resumption, companies in the sector have the opportunity to adapt with greater predictability and assertiveness. If your company needs specialized support to stay compliant with Anvisa’s requirements, contact QR Group and count on our expertise to navigate the complex Brazilian regulatory landscape.

Source: ANVISA